NKF's KidneyCARE™ Study Celebrates One-Year Milestone, Enrolling Over 1,000 Patients Nationwide
The National Kidney Foundation (NKF) is proud to announce that its KidneyCARE (Community Access to Research Equity)™ Study – ...
The Manila Times1h
Novartis receives third FDA approval for oral Fabhalta® (iptacopan) - the first and only treatment approved in C3 glomerulopathy (C3G)
Novartis receives third FDA approval for oral Fabhalta® (iptacopan) - the first and only treatment approved in C3 glomerulopathy (C3G) Phase III study showed sustained proteinuria reduction at one ...
Climb Bio: Meet The Newest Star in Autoimmune Disease Treatment – Initiation Report
By Rayk Riechmann As one of the brightest emerging biotechnology companies, Climb Bio Inc. (NASDAQ: CLYM) aims to improve the ...
Le Lézard11h
NKF's KidneyCAREtm Study Celebrates One-Year Milestone, Enrolling Over 1,000 Patients Nationwide
The National Kidney Foundation (NKF) is proud to announce that its KidneyCARE (Community Access to Research Equity)tm Study ? the first national CKD patient registry that captures both ...
pharmaphorum6d
Biogen shows its IgAN hand with felzartamab data
Biogen has revealed encouraging phase 2 results with its anti-CD38 antibody felzartamab in rare kidney disease IgA nephropathy (IgAN), which it hopes could join a series of first-in-class ...
pharmaphorum6d
Vertex wagers $4.9bn on Alpine kidney disease therapy
The disease affects around 130,000 people in the US and another 115,000 in Europe. The new results from the phase 1b/2a RUBY study in 41 IgAN patients showed that povetacicept given by ...
Travere Therapeutics Submits sNDA to FDA for Approval of FILSPARI® (sparsentan) for the Treatment of FSGS
NDA submission based on results from Phase 3 DUPLEX and Phase 2 DUET studies of FILSPARI in FSGSIf approved, FILSPARI could become the first and ...
Travere Therapeutics, Inc.: Travere Therapeutics Submits sNDA to FDA for Approval of FILSPARI (sparsentan) for the Treatment of FSGS
NDA submission based on results from Phase 3 DUPLEX and Phase 2 DUET studies of FILSPARI in FSGS If approved, FILSPARI could become the first and only FDA-approved treatment for FSGS, a rare kidney ...
Autoimmune diseases & kidney health: How do autoimmune diseases affect the kidneys?
Autoimmune diseases make the immune system attack healthy tissues. These can affect organs like kidneys, leading to ...
Travere Therapeutics, Inc. (NASDAQ:TVTX) Receives $30.62 Average Price Target from Analysts
Shares of Travere Therapeutics, Inc. (NASDAQ:TVTX – Get Free Report) have been assigned a consensus recommendation of “Moderate Buy” from the fourteen research firms that are covering the stock, ...
Bank of New York Mellon Corp Raises Stock Holdings in Travere Therapeutics, Inc. (NASDAQ:TVTX)
Bank of New York Mellon Corp grew its position in Travere Therapeutics, Inc. (NASDAQ:TVTX – Free Report) by 3.6% in the 4th quarter, according to its most recent disclosure with the Securities and ...
Biogen Inc. (BIIB) Stifel 2025 Virtual CNS Forum Conference (Transcript)
Biogen Inc. ( NASDAQ: BIIB) Stifel 2025 Virtual CNS Forum Conference March 18, 2025 10:15 AM ET Great. Good morning, everybody. Happy to be moderating my annual panel where Priya has to listen to me ...